Faculty & Staff

Jungyeon Moon, PhD, MS, BS

Jungyon Moon
Areas of Expertise

Cardiovascular Pharmacotherapy, Medication Adherence and Persistence, Health Outcomes Research, Evidence-based Medicine, Heart Failure and Cardiovascular Risk Reduction

Featured Links

Google Scholar

Dr. Jungyeon Moon joined Keck Graduate Institute in September 2024 as an Assistant Professor of Clinical Sciences. She is a Clinical and Academic Pharmacist with over 20 years of experience in patient care, education, and clinical research. Dr. Moon holds a PhD, MS, and BS in Clinical Pharmacy from Ewha Womans University in Seoul, South Korea, and earned her PharmD from Western University of Health Sciences in 2020.

Dr. Moon spent over 12 years as a Clinical Pharmacist at Seoul National University Hospital (SNUH), where she also completed her PGY1 and Integrated Clinical Pharmacy Residency (PGY2). During her time at SNUH, she specialized in anticoagulation management, serving as Director of the anticoagulant residency program, and gained significant expertise in cardiovascular pharmacotherapy.

After moving to the United States, Dr. Moon pursued her PharmD at WesternU, followed by a Cardiovascular Outcomes Research Fellowship. Her fellowship training included clinical practice at WesternU and the VA West Los Angeles Healthcare Center, focusing on heart failure management and cardiovascular risk reduction.

At KGI, Dr. Moon teaches therapeutic courses and mentors PharmD students, emphasizing cardiovascular pharmacotherapy, medication adherence, and innovative research methodologies. She has published research articles in peer-reviewed journals, with research interests spanning cardiovascular disorders, quality of cardiovascular medication utilization, patient education and adherence, medication prescribing patterns, evidence-based medicine, medication costs, and drug interaction and safety.

  • Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. Comparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes. Am J Cardiol. 2024 May 1:S0002-9149(24)00329-1.
  • Moon J, Udell JA, Chong A, Fang J, Austin PC, Ko DT, Stukel TA, Atzema CL, Booth GL, Tu K, Naimark DMJ, Jackevicius CA. Time to SGLT2 inhibitors initiation in patients with heart failure. J Am Heart Assoc. 2024 Apr;13(8):e032296.
  • Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5704.
  • Ton IT, Moon J, Sengul A, Mody FV, Rahman T, Han JK, Jackevicius CA. Evidence-based cardiovascular disease medicines’ availability in low-cost generic drug programs in the United States. Ann Intern Med. 2023 Sep;176(9):1190-1199.
  • Moon J, Jackevicius CA. Evidence-based appraisal of the EMPEROR-Preserved Trial. J Contemp Pharm Pract. 2022;69(3):13-17.
  • Cohen Sedgh R, Moon J, Jackevicius CA. Neoplasm reports in food and drug administration adverse event reporting system following angiotensin receptor blocker recalls. Circ Cardiovasc Qual Outcomes. 2021 Aug;14(8):e007476.
  • Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins through statin adverse events reported in the FDA adverse event reporting system (FAERS). Circ Cardiovasc Qual Outcomes. 2021 Jan;14(1):e007480.
  • Moon J, Chang Y, Shah T, Min DI. Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients. Transpl Infect Dis. 2020 Aug;22(4):e13300.
  • Moon J, Chang Y, Shah T, Min DI. Effect of tacrolimus metabolism rate on renal function among hispanic kidney transplant recipients. Biomedical J Sci Tech Res. 2020 Jan;24(2):18042-18049.
  • Moon JY, Kim Y, Huh JW, Cho EJ, Kim HS, Jo YS, Han HJ, Choi EK. Feasibility of extending INR recall intervals for patients with atrial fibrillation on warfarin therapy: a retrospective observational study. J Kor Soc Health-syst Pharm. 2017 Feb;34(1):26-34.
  • Moon JY, Kim BR, Jo EJ, Cho YS, Han HJ, Choi EK. Evaluation of peri-procedural warfarin therapy undergoing cardioversion in patients with atrial fibrillation. Kor J Clin Pharm. 2016 Sep; 26(3):201-206.
  • Seo BC, Moon JY, Jo EJ, Cho YS, Hahn HJ. A Retrospective evaluation of vitamin K1 therapy for managing supratherapeutic INR in non-bleeding patients treated with warfarin. J Kor Soc Health-syst Pharm. 2016 Nov;33(4):333-340.
  • Moon JY, Gwak HS. Role of the nuclear pregnane X receptor in drug metabolism and the clinical response. Receptors Clinl Investig. 2015 Nov;2:e996.
  • Moon JY, Lee KE, Chang BC, Jeong E, Jeong H, Gwak HS. Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses. Pharmacogenet Genomics. 2015 Jan;25(1):38-40.
  • Moon JY, Park HH, Im JM, Lee YH, Lee HS, Han HJ. Analysis of potential drug interaction with warfarin therapy in hospitalized patients. J Kor Soc Health-syst Pharm. 2015 May;32(2):93-103.
  • Moon JY, Chang BC, Lee KE, Gwak HS. Effects of pregnane X receptor genetic polymorphisms on stable warfarin doses. J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):532-538.
  • Moon JY, Kim SW, Lee KE, Gwak HS. Correlation between aggression and health behaviors of Korean high school students. Kor J Clin Pharm. 2014 Jun;24(2):144-153.
  • Lee YS, Moon JY, Hahn HJ, Son IJ, Oh JM. Drug use evaluation of 5-HT3 receptor antagonist in medical insurance. J Kor Soc Health-syst Pharm. 2007 Sep;24(3):219-222.
  • Moon JY, Kim KS, Moon SR, Hahn HJ, Son IJ. Study of the ease of tablet administration in pediatric prescriptions. J Kor Soc Health-syst Pharm. 2003 Dec;20(4):490-497.